GSKGlaxoSmithKlineSigning up patients
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Ovarian Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 450 (planned)
- Started
- Jun 18, 2026
- Main results expected
- Jul 22, 2030
- Fully finished
- Jul 22, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) by BICR
Measured over: Up to approximately 212 weeks
Overall Survival (OS)
Measured over: Up to approximately 212 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07286266 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC